Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.54 |
| ▸ | TACR1 | P25103 | 19/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31599475 | 1.00 | SLC6A2 (0.54) | SLC6A2TACR1MAPT | |
| SCHEMBL29696994 | 0.88 | TACR1 (0.48) | SLC6A2TACR1MAPT | |
| SCHEMBL29696977 | 0.86 | NMUR2 (0.56) | SLC6A2 | |
| SCHEMBL31599477 | 0.86 | OPRM1 (0.49) | SLC6A2 | |
| SCHEMBL30866227 | 0.84 | TACR1 (0.53) | SLC6A2TACR1 | |
| SCHEMBL29697005 | 0.84 | NMUR2 (0.57) | SLC6A2 | |
| SCHEMBL29453074 | 0.83 | SLC6A2 (0.65) | SLC6A2 | |
| SCHEMBL29697064 | 0.83 | NMUR2 (0.55) | — | |
| SCHEMBL30424040 | 0.81 | SLC6A2 (0.62) | SLC6A2 | |
| SCHEMBL30051364 | 0.80 | DPP3 (0.60) | SLC6A2TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113861268-B | Cell penetrating peptides and methods of making and using the same | 恩特拉达治疗学股份有限公司 | 2025-04-01 | — | — | CN | disclosed |
| US-20250011367-A1 | CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | ENTRADA THERAPEUTICS, INC. | 2025-01-09 | — | — | US | disclosed |
| US-20220177523-A1 | CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | ENTRADA THERAPEUTICS, INC. | 2022-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011367-A1 | CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | VIP, LNPEP, TAP1 | SLC6A2 2612/4885TACR1 770/4885MAPT 3736/4885 |
| US-20220177523-A1 | CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | VIP, LNPEP, TAP1 | SLC6A2 2612/4885TACR1 770/4885MAPT 3736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.